GlassScriptPhysician profile
Vijay Subramanian
NPI 1932549359
$21,625.71
in general payments reported to CMS, 2019-2025
11 companies · $10K in 2025
The $10K reported for 2025 was more than what 91% of Transplant Surgery providers received nationally (typical 2025 total: $423).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95.66 · 2020: $120 · 2021: $82.81 · 2022: $393 · 2023: $1,925 · 2024: $8,707 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $6,285 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,923 · Consulting Fee: $3,724 · Honoraria: $3,200 · Food and Beverage: $2,029 · Education: $1,590 · Gift: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $6,285.22 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,923.00 |
| Consulting Fee | $3,723.61 |
| Honoraria | $3,200.00 |
| Food and Beverage | $2,029.35 |
| Education | $1,589.99 |
| Gift | $182.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organox LTD | $18,575.23 | 2023-2025 | Metra |
| Intuitive Surgical, INC. | $1,502.81 | 2021-2023 | Davinci Xi |
| Baxter Healthcare | $385.85 | 2024-2025 | Tisseel, Renal - Acute |
| Veloxis Pharmaceuticals, INC. | $383.35 | 2019-2022 | |
| Boston Scientific Corporation | $269.34 | 2020-2023 | Therasphere Y90 Glass Microspheres 10 Gbq |
| La Jolla Pharmaceutical Company | $163.13 | 2022 | |
| Integra Lifesciences Corporation | $153.94 | 2024 | Integra, Integra Dermal Regeneration Template, Omnigraft |
| Jazz Pharmaceuticals INC. | $89.99 | 2023 | |
| Paragonix Technologies, INC. | $80.16 | 2024 | Pancreaspak, Liverguard, Sherpapak |
| Electromed, INC. | $21.91 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vijay Subramanian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.